IMMUNOTHERAPY

Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

The PD-1 blocking antibody nivolumab continues to demonstrate clinical activity in previously treated patients with advanced non-small cell lung cancer (NSCLC), according to updated long-term survival data from a phase I trial.

Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.

Targeted Oncology spoke with Padmanee Sharma, MD, PhD, about advances in immunotherapy for castration-resistant prostate cancer (CRPC).

Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses immune response in renal cell carcinoma.

At the 11th International Congress on Targeted Therapies in Cancer, The International Journal of Targeted Therapies in Cancer spoke with Dr. Sosman about his conference presentation on advances in immunotherapy in melanoma.

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses treatment decisions for patients with melanoma.

With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing immunotherapy and targeted therapy for patients with melanoma.

MK-3475, an investigational immunotherapy, has demonstrated an objective response rate (ORR) of up to 24% in patients with previously treated non-small cell lung cancer (NSCLC), according to interim results from a phase Ib expansion study.

Karl Lewis, MD, discusses new and emerging treatments for metastatic melanoma.

Roy S. Herbst, MD, PhD, discusses targeting PD-1 and PD-L1 when treating patients with lung cancer.

Jeffrey A. Sosman, MD, discusses how immunotherapies work in patients with melanoma or renal cancer.

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

The human epidermal growth factor receptors (known as the HER family) play a pivotal role in transmitting signals that regulate cell growth and survival.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, discusses the background of the prophage G-200 vaccine for recurrent glioblastoma multiforme.

The efficacy of combining two immunotherapy agents will be assessed in a randomized, double-blind phase III study.

Julie R. Brahmer, MD, Associate Professor, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses patient response to immunotherapy.

Howard L. Kaufman, MD, says that the oncology community is in its infancy in terms of selecting and sequencing immunotherapies for patients with melanoma.

Catherine Bollard, MBChB, MD, from the Baylor College of Medicine, discusses T cells and TGF-beta in Hodgkin's lymphoma and Non-Hodgkin lymphoma.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Pazopanib was better tolerated with noninferior efficacy when compared to sunitinib as a treatment for patients with advanced renal cell carcinoma.

Elizabeth Mittendorf, MD, PhD, from the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.